Académique Documents
Professionnel Documents
Culture Documents
Hair loss in children can cause psychological stress to the parent and patient alike. Alopecia can be
classified into congenital and acquired. Commonly encountered causes of pediatric alopecia (tinea
capitis, alopecia areata, traction alopecia and trichotillomania) are reversible if diagnosed early. Special
note should be made of the extent and type of alopecia (scarring or nonscarring), any hair shaft
anomalies and signs of inflammation. Diagnostic evaluation includes a bewildering array of age-old
simple bedside tests (e.g., potassium hydroxide preparation) to state-of-the art accurate instruments
(e.g., trichoscan). Systemic antifungal therapy is required for tinea capitis. Topical and systemic
immunomodulators are currently being employed for treating alopecia areata. A holistic approach would
include not just therapeutic intervention but also an active search for associated nutritional deficits,
underlying psychosocial disturbances and behavioral problems, the latter two requiring counseling and
behavior therapy. Children with permanent hair loss can be offered surgical hair transplantation or
camouflage devices, such as wigs.
Introduction
Though losing hair is not usually health threatening, it can scar a young child's vulnerable self esteem by
causing immense psychological and emotional stress; not just to the patient, but also to the concerned
parents and siblings. Thus, management of hair disorders can be quite a daunting task for the attending
physician and mandates a holistic approach to the patient. Nevertheless, an organized diagnostic and
management strategy can turn this challenging task into an interesting and fruitful exercise.
To fully understand hair loss in childhood, a basic knowledge of normal hair growth is necessary. The
normal hair cycle is divided into four phases: the active growth anagen phase, followed by a brief
catagen phase, the resting telogen phase and finally the shedding exogen phase. [1] Typically, 8595% of
hairs are in the anagen phase, which lasts approximately 3 years. Less than 1% of hairs are in catagen,
the transitional phase, which lasts from a few days to weeks. The telogen phase (which accounts for 5
15% of hairs and lasts about 3 months) ends when the new anagen hair emerges from the follicle.
For the classification of pathological hair loss in children, two major groups should be differentiated:
congenital and acquired hair loss.[2,3] This distinction is the first step in diagnosis ( & Figure 1).
Pathological hair loss, although rare in the first year of life, may be a symptom of an underlying
congenital syndrome or clue to an underlying metabolic disorder which may have a bearing on the
mental and physical development of a child.[46]
Box 1. Age-wise distribution of common causes of alopecia.
Preschool
Genotrichosis
Alopecia areata
Occipital alopecia
School going
Tinea capitis
Alopecia areata
Trichotillomania
Telogen effluvium
Traction alopecia
Adolescents
Telogen effluvium
Alopecia areata
Androgenetic alopecia
Triangular alopecia
Figure 1.
Diffuse alopecia
Isolated hair shaft anomalies presenting with hair breakage (in some cases with
associated defects):
o
Trichorrhexis nodosa
Monilethirix
Pseudomonilethrix
Pili torti
Netherton's syndrome
Menkes syndrome
Trichothiodystrophy
Ectodermal dysplasia
Arginosuccinicaciduria
Congenital hypotrichosis and atrichia with papular lesions (can be associated with
syndromes)
Production decline:
o
Anagen loss:
Anagen effluvium
Telogen loss:
Telogen effluvium
Focal alopecia
Scarring:
o
Trauma
Aplasia cutis
Nevoid condition
Syndromic associations
Folliculitis decalvans
DLE, LPP
Nonscarring:
o
Alopecia areata
Tinea capitis
Traction alopecia
Trichotillomania
Obvious physical or emotional triggers in the previous 25 months, and any accompanying
complaints (e.g., fatigue, weight changes, and nail or skin abnormalities);
Thorough examination of scalp as well as the other hair-bearing areas of the body, especially
loss of axillary and pubic hair, eyelashes, eyebrows and body hair;
Any hair shaft anomalies, hair quality, color, roughness and tendency to breakage, 'exclamationpoint' hairs;
Approximately 20 hairs are grasped and firmly tugged away from the scalp;
>10% of grasped hairs or two hairs suggests positive pull test and active hair shedding.
The skin, nails, oral or genital mucous membranes (e.g., for evidence of associated dermatoses,
such as lichen planus);
Thorough clinical examination of the entire head and body is necessary in order to evaluate
impaired vision, defective hearing, dysmorphic features, clues to autoimmune or metabolic
diseases, or ectodermal anomalies.
Diagnostic Procedures
When tinea capitis is suspected:
Fungal culture by scraping the affected areas with a blunt scalpel, a sterile brush or moistened
gauze to gather affected hairs;
A potassium hydroxide preparation (to reveal hyphae): a scalp scraping or plucked hairs from
the affected area.
Thyroid function
Serum ferritin;
Antinuclear antibody;
Keratin analysis.
Newer techniques:[714]
Videodermoscopy: the magnified images of hair follicle are useful for the differential diagnosis
between cicatricial and noncicatricial alopecia and between alopecia areata and trichotillomania;
Trichoscan: it is an automated software program for the accurate analysis of hair growth and
useful in monitoring the response to treatment;
Tinea capitis is the commonest cause of patchy hair loss in children in the developing world owing to
poor socioeconomic conditions.[15] It is an infection of the scalp and associated hair, caused by
dermatophytes (generaTrichophyton and Microsporum except Trichophyton concenticum). The most
common cause is Trichophyton tonsuransin the USA and UK and Microsporum canis in the rest of the
world.[16,17] A clinician should be aware of its variable morphological presentations such as circular patches
of alopecia and marked scaling (grey patch type), black dots indicating broken hair (black dot type),
diffuse widespread scaling (seborrheic type), boggy nodules studded with pustules (kerion type) and
yellow crusts (scutula) that surround hair follicles with a peculiar musky odour (favus type caused
by Trichophyton schoenleinii).
Tinea capitis, once proven by culture or potassium hydroxide, requires systemic treatment. Flouroscence
by woods lamp is only displayed by a few species, so it is not a very sensitive tool in detection of tinea
capitis. Treatment is outlined in .[1821]
Table 1. Treatment options for tinea capitis.
Pharmacologic
agent
Regimen
Itraconazole
5 mg/kg/day in 68 weeks
Fluconazole
Terbenafine
Adjuncts:
Topical selenium
sulphide shampoo
Zinc pyrithone
shampoo
Ketoconazole
shampoo
Povidone Iodine
shampoo
RCT: Randomized controlled trial.
Alopecia Areata
Alopecia areata (AA) is a chronic, organ-specific autoimmune disease, mediated by autoreactive T cells,
which affects hair follicles and sometimes the nails. Evidence of the autoimmune nature includes
reported associations between AA and other autoimmune disorders (e.g., Hashimoto thyroiditis) and,
histopathologically, the presence of lymphocytes around the hair bulb in a pattern resembling a swarm of
bees.[2223]
The characteristic lesion of AA is commonly an oval, totally bald, smooth patch involving the scalp or any
hair-bearing area on the body. A characteristic feature of an AA patch is 'exclamation-mark' hairs (broken,
short hairs that taper proximally) that may be present at its margin. The clinical presentation of AA is
subcategorized according to pattern or extent of the hair loss. It can be classified according to pattern as
classical patchy AA (most common), reticulated pattern of AA, ophiasis band like AA (hair loss in the
parietal temporo-occipital scalp) and sisaphio (a band of hair loss in the frontal parieto-temporal scalp).
[24]
If categorized according to extent of involvement, the following forms may be seen: alopecia areata
with partial loss of scalp hair; alopecia totalis (100% loss of scalp hair) and alopecia universalis (100%
loss of hair on the scalp and body).[22]
Indicators of a poor prognosis are the presence of other immune diseases, atopy, family history of AA,
young age at onset, nail dystrophy, extensive hair loss and ophiasis pattern. [23]
In the majority of patients, hair regrows entirely within 1 year without treatment. Because of the chance
for spontaneous resolution, it is often reasonable to do watchful waiting and reassurance initially. Should
the alopecia continue to worsen or persist, a therapy can be considered. It is helpful to get the patient
involved in a support group and/or counseling from the very first visit. The treatment of alopecia depends
on the extent of involvement and the age of the patient. In localized involvement, commonly used agents
include topical and intralesional corticosteroids, topical anthralin and minoxidil. In widespread
involvement, contact sensitization (e.g., diphenylcyclopropenone) and oral immunosuppressives are
usually resorted to.
Various treatment options are discussed in .[22,2552]
Table 2. Treatment options for alopecia areata.
Treatment
Advantages
Disadvantages
Nonsystemic therapy
Easy to apply at home
Topical corticosteroids
Painless
Intralesional corticosteroids
Painful
Good response in
majority cases
Baxarotene
Dermal irritation
Prostaglandin analogue
(latanoprost, bimatoprost)
Well tolerated
Minoxidil
Nonirritant
Variable results
Nonirritant
Calcineurin inhibitors
Poor results
Easy to use
Excellent results
reported
Expensive
Expensive option
Systemic therapy
Systemic corticosteroids
PUVA
Methotrexate
Sulfasalazine
Relatively safe
IVIG
Safe in pregnancy
Expensive
Scanty data
Biologicals (alefacept,
adalimumab, etanercept,
efalizumab)
Poor response
Expensive
Side effect profile
Ciclosporin
Useful in widespread
cases
Infrared irradiation
IVIG: Intravenous immunoglobulin; PUVA: Psoralen plus UVA; RCT: Randomized controlled trial.
Trichotillomania
Sometimes preferentially referred to as trichotillosis (as the suffix mania can connote insanity)
trichotillomania refers to compulsive habit or desire to pull out the hair.[5355] The clinical manifestation is
usually quite distinctive, with a confluence of twisted and broken off hairs within an otherwise normal area
of the scalp. Counselling, psychotropic drugs such as clomipramine or sertraline, N-acetyl cysteine and
behavior modification techniques (e.g., habit-reversal therapy) are effective treatment options. [5662] As
glutamatergic dysfunction has been implicated in the pathogenesis of obsessivecompulsive disorder; Nacetylcysteine, a glutamate modulator, is a novel therapeutic agent found to be effective in
trichotillomania.
Traction Alopecia
Traction alopecia is caused by prolonged traction of scalp hair by use of hair styles, such as tight braids
and high pony tails, among others. Though usually the alopecia is reversible, if the traction is continued
over years, mechanical damage to hair follicles may result in permanent hair loss. [63,64] Cessation of the
offending hair practice is the treatment.
Syphilitic Alopecia
It may be the first sign of syphilis and can present as typical motheaten alopecia, generalized thinning of
the hair or may mimic alopecia areata. A high index of suspicion is required to diagnose this entity,
especially in sexually active adolescents.[65]
Although predominantly a disease of adults, children can rarely be affected. Clinical hallmarks of active
disease include perifollicular violaceous papules and follicular hyperkeratosis. Histopathology
demonstrates the diagnostic features of lichenoid interface alteration. Limited disease is managed with
topicalor intralesional steroids. For those with rapidly progressive or extensive lesions, steroids, retinoids
or antimalarials are considered.[6669]
Linear Scleroderma
Most often seen in the first decade of life, linear scleroderma can present on the frontal scalp extending
to the forehead (en coup de sabre) as a linear shiny plaque with binding down of skin. It may be
associated with underlying bony, eye and CNS defects and requires a complete radiological work up to
exclude associated abnormalities. Histopathology reveals increased collagen in dermis with reduced
pilosebaceous appendages. Early diagnosis is important to halt the active inflammatory phase by
instituting treatment in the form of immunomodulators, such as steroids and hydroxychloroquine. [70]
It presents as well-circumscribed triangular or ovoid patch of alopecia that involves the temporal region.
[71]
Vellus hair is present in the affected area. There is no effective treatment.
Aplasia Cutis Congenita
Aplasia cutis congenita constitutes a group of disorders that present at birth with eroded areas in the
scalp or body with or without other developmental anomalies.[72,73] The scalp erosions are characterized
by absence of a part of skin which heals spontaneously over a period of time and manifests as a patch of
cicatricial alopecia.
Nevus Sebaceous
Nevus sebaceous of Jadassohn is a common clinical entity which belongs to the group of epidermal nevi,
usually manifesting early in life in the form of an orange, waxy hairless circumscribed plaque most
commonly localized on the head and neck area.[74] It may be part of epidermal nevus syndrome in
association with other development anomalies. Excision is recommended in view of potential to develop
cutaneous malignancies.
Keratosis Follicularis Spinulosa Decalvans
Hereditary simple hypotrichosis is a rare group of familial nonscarring hypotrichosis and atrichias without
associated internal abnormalities. Most of them are inherited in an autosomal dominant pattern. [7678]
Woolly Hair Hypotrichosis
It is characterized by tightly coiled, markedly curly and short hair. It may be associated with eye and teeth
defects, deafness, palmoplantar keratoderma and cardiac abnormalies (Naxos disease).
Ectodermal Dysplasias
These genodermatoses are characterized by absent or inadequate development of one or more of the
epidermal appendages namely hair, sweat glands, sebaceous glands, nails and teeth.
Genetic Syndromes With Hair Shaft Anomalies
Trichorrhexis Nodosa In light microscopy, trichorrhexis nodosa, shows hair fracture with individual
cortical cells and their fragment splaying-out resembles two brushes whose ends are pushed together. [90
92]
Loose Anagen Syndrome Loose anagen syndrome is a disorder of anagen hair anchorage to the hair
follicle, characterized by the ability to easily and painlessly pull out large numbers of anagen hairs from
the scalp. Physical examination shows sparse growth of thin, fine hair and diffuse or patchy alopecia
without inflammation or scarring. Trichogram demonstrates 98100% of plucked hairs to be anagen
hairs. Light microscopy may reveal ruffling of the cuticle adjacent to the anagen bulb giving a 'floppy
sock' appearance. In most patients the condition improves spontaneously.[9496]
Telogen Effluvium
Telogen effluvium refers to an abnormality of the normal hair cycle leading to excessive loss of telogen
hair. Frequent triggers include physiologic effluvium of the newborn, febrile illnesses, catabolic illnesses,
such as malignancies, hypothyroidism, medications (e.g., retinoids and valproate), stress, surgery, caloric
or protein deprivation and chronic iron deficiency. Assuming there is no intervening pathological process,
the loss is usually replaced in 612 months. Treatment revolves around addressing the underlying cause.
[97,98]
Anagen Effluvium
Anagen effluvium is the abrupt loss of 8090% of hair, which occurs when the anagen phase is
interrupted. Radiotherapy to the head, systemic chemotherapy especially alkylating agents (e.g.,
cyclophosphamide) and exposure to toxic agents are usually the inciting events. These agents disrupt
the anagen cycle and cause varying degrees of hair follicle dystrophy. Replacement with a normal pelage
usually occurs rapidly after discontinuation of chemotherapy, but radiotherapy can cause permanent
scarring alopecia.[99103]
Androgenetic alopecia encompasses male pattern hair loss and female pattern hair loss and is identified
as the most frequent cause of hair loss in adolescents (male:female ratio of 2:1). It is usually due to
action of dihydrotestosterone on a genetically susceptible hair follicle leading to progressive hair
miniaturization. In adolescent girls the most common patterns of hair loss are centrifugal loss at the
crown and the frontal accentuation or 'christmas tree' pattern. In adolescent boys it commonly manifests
as bitemporal recession and thinning in the frontal and vertex. Although the pathogenesis remains
speculative, endocrine evaluation and a strict follow-up are recommended in prepubertal patients with
androgenetic alopecia. Topical minoxidil and finasteride (only in male patients) is effective. [102]
Expert Commentary
Diagnosing a given case of childhood alopecia is not just crucial for preventing irreversible hair loss, but
may also turn out to be the necessary clue to an otherwise unfathomable multisystem illness or an
explanation for an unexplained developmental delay. The most frequent causes of childhood alopecia
(tinea capitis, alopecia areata, traction alopecia and trichotillomania) are usually reversible if detected
early. The evaluation of a child with scalp hair loss should always include a detailed history, physical
examination and microscopic examination of the hair. A thorough examination of scalp, skin, mucosa,
teeth, nails and relevant systemic examination can be helpful in clinching accurate diagnosis. Newer
techniques, such as videodermoscopy, trichoscan and contrast-enhanced phototrichogram aid in solving
clinical dilemmas.
Congenital alopecia remains a largely neglected area with not many treatment options. There is a well
perceived need for hair clinics dedicated solely to the study of disorders causing hair loss. Newer
therapeutic armentatorium for alopecia areata, such as baxarotene, lasers (excimer, pulse infrared diode,
fractional photothermolysis) and infrared irradiation has been found to be useful while biologicals and
prostaglandin analogues (latanoprost, bimatoprost) has been found to be ineffective. N-acetylcysteine
has been found useful in trichotillomania. Counseling and support groups can be invaluable to reduce
psychological sequelae. Promising modalities for scarring alopecias are alginate gel implantation with
microencapsulation of hair follicle stem cell and dermal papilla cells.
Five-year View
Recent advances in epithelial stem cell biology have led to successful isolation of hair follicle stem cells,
which creates the opportunity to bioengineer hair follicles for the treatment of hair loss.
Utilizing effectiveness of alginate gel in cell implantation, microencapsulation of the hair follicle stem cells
and dermal papilla cells can be implanted into the bald scalp of the patient. As both follicle stem cells and
dermal papilla cells have strong proliferative capacity, the patient's own cells could be expanded
considerably in vitro.[103105] A genome-wide association study, which implicates T-cell and natural killer cell
activation pathways, has opened the window for new approaches in future clinical trials of alopecia
areata. Future treatment approaches for alopecia areata include use of drugs that block the NKGDactivating ligand and NKG2D receptor interaction, halt activated T cells, or modification of the
inflammatory cytokine network (e.g., anti-CD25, anti-CTLA-4, Jak 1/2 inhibitor, anti-NKG2D, Syk
inhibitor).[26]
Congenital alopecias remain a domain of orphan diseases with little to offer in terms of treatment except
camouflage and wigs. Research to refine knowledge of genes controlling the differentiation of hair
follicles is likely to develop treatment breakthroughs, such as gene therapy.
Sidebar
Key Issues
Acknowledging patients' concerns and having an empathetic approach to hair loss goes a long
way. Patients often appreciate a supportive diagnostic and therapeutic approach.
Although alopecia has myriad causes, a careful study of history, close attention to the
appearance of the hair loss and a few simple tests can quickly narrow the potential diagnoses.
Scarring alopecias, although rare, are considered true trichologic emergencies as hair loss can
be irreversible if prompt appropriate therapy is not instituted.
Frequent causes of nonscarring focal alopecia are usually treatable (tinea capitis, alopecia
areata, traction alopecia and trichotillomania).
Evaluation of alopecia in infants should include recording of family history to exclude genetic
disorders and examination of teeth, nails, skeletal system and the eyes, along with a thorough
systemic examination.
Androgenetic alopecia can be the presenting sign of an underlying endocrine disorder in preadolescents.
Offering psychosocial support and nonpharmacologic techniques to help the child appear more
like their peers should be part of care.
References
1.
Tiede S, Kloepper JE, Bodo E et al. Hair follicle stem cells: walking the maze. Eur. J. Cell
Biol. 86(7), 355376 (2007).
2.
Tosti A, Gray J. Assessment of hair and scalp disorders. J. Investig. Dermatol. Symp.
Proc. 12(2), 2327 (2007).
3.
Hillmann K, Blume-Peytavi U. Diagnosis of hair disorders. Semin. Cutan. Med. Surg. 28(1), 33
38 (2009).
4.
5.
6.
Tielsch Goddard A. Hair loss in an adolescent. J. Pediatr. Health Care 25(4), 261265 (2011).
Excellent review outlining the approach to alopecia in the adolescent population, delving into
pharmacologic as well as nonpharmacologic treatment options and outlining the importance of
psychological support to the vulnerable adolescent patient.
7.
Gassmueller J, Rowold E, Frase T et al. Validation of TrichoScan technology as a fullyautomated tool for evaluation of hair growth parameters. Eur. J. Dermatol. 19(3), 224231
(2009).
8.
Dhurat R, Saraogi P. Hair evaluation methods: merits and demerits. Int. J. Trichology 1(2), 108
119 (2009).
9.
Van Neste D, Leroy T, Conil S. Exogen hair characterization in human scalp. Skin Res.
Technol. 13(4), 436443 (2007).
10. Hughes R, Chiaverini C, Bahadoran P, Lacour JP. Corkscrew hair: a new dermoscopic sign for
diagnosis of tinea capitis in black children. Arch. Dermatol. 147(3), 355356 (2011).
11. Iorizzo M, Pazzaglia M, Starace M, Militello G, Tosti A. Videodermoscopy: a useful tool for
diagnosing congenital triangular alopecia. Pediatr. Dermatol. 25(6), 652654 (2008).
12. Wallace MP, de Berker DA. Hair diagnoses and signs: the use of dermatoscopy. Clin. Exp.
Dermatol. 35(1), 4146 (2010).
Good evaluation of the utility of a new diagnostic aid and its advantages and limitations.
13. Rudnicka L, Olszewska M, Rakowska A, Kowalska-Oledzka E, Slowinska M. Trichoscopy: a new
method for diagnosing hair loss. J. Drugs Dermatol. 7(7), 651654 (2008).
14. Tonci RJ, Lipozenci J, Pastar Z.Videodermoscopy in the evaluation of hair and scalp
disorders. Acta Dermatovenerol. Croat. 15(2), 116118 (2007).
15. Ali S, Graham TA, Forgie SE. The assessment and management of tinea capitis in
children. Pediatr. Emerg. Care 23(9), 662665 (2007).
29. Pan Y, Rao NA. Alopecia areata during etanercept therapy. Ocul. Immunol. Inflamm. 17(2), 127
129 (2009).
30. Kirshen C, Kanigsberg N. Alopecia areata following adalimumab. J. Cutan. Med. Surg. 13(1),
4850 (2009).
31. Roseborough I, Lee H, Chwalek J, Stamper RL, Price VH. Lack of efficacy of topical latanoprost
and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia
areata. J. Am. Acad. Dermatol. 60(4), 705706 (2009).
32. Kamel MM, Salem SA, Attia HH. Successful treatment of resistant alopecia areata with a
phototoxic dose of ultraviolet A after topical 8-methoxypsoralen application. Photodermatol.
Photoimmunol. Photomed. 27(1), 4550 (2011).
33. Ohtsuki A, Hasegawa T, Ikeda S. Treatment of alopecia areata with 308-nm excimer lamp. J.
Dermatol. 37(12), 10321035 (2010).
34. Pugashetti R, Koo J. Phototherapy in pediatric patients: choosing the appropriate treatment
option. Semin. Cutan. Med. Surg. 29(2), 115120 (2010).
35. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: part II.
Treatment. J. Am. Acad. Dermatol. 62(2), 191202 (2010).
Detailed overview of topical and systemic therapeutic armamentarium including table
summaries of recommendations.
36. Lee JW, Yoo KH, Kim BJ, Kim MN. Photodynamic therapy with methyl 5-aminolevulinate acid
combined with microneedle treatment in patients with extensive alopecia areata. Clin. Exp.
Dermatol. 35(5), 548549 (2010).
37. Al-Mutairi N. 308-nm excimer laser for the treatment of alopecia areata in children. Pediatr.
Dermatol. 26(5), 547550 (2009).
38. Yoo KH, Kim MN, Kim BJ, Kim CW. Treatment of alopecia areata with fractional
photothermolysis laser. Int. J. Dermatol. 49(7), 845847 (2010).
39. Garg S, Messenger AG. Alopecia areata: evidence-based treatments. Semin. Cutan. Med.
Surg. 28(1), 1518 (2009).
40. Ito T, Aoshima M, Ito N, Uchiyama I, Sakamoto K, Kawamura T et al. Combination therapy with
oral PUVA and corticosteroid for recalcitrant alopecia areata. Arch. Dermatol. 301(5), 373380
(2009).
41. Mavilia L, Mori M, Rossi R, Campolmi P, Puglisi Guerra A, Lotti TG. 308 nm monochromatic
excimer light in dermatology: personal experience and review of the literature. Ital. Dermatol.
Venereol. 143(5), 329337 (2008).
42. Fernndez-Guarino M, Harto A, Garca-Morales I, Prez-Garca B, Arrazola JM, Jan P. Failure
to treat alopecia areata with photodynamic therapy. Clin. Exp. Dermatol. 33(5), 585587 (2008).
43. Rashidi T, Mahd AA. Treatment of persistent alopecia areata with sulfasalazine. Int. J.
Dermatol. 47(8), 850852 (2008).
44. Bakar O, Gurbuz OJ. Is there a role for sulfasalazine in the treatment of alopecia areata? Am.
Acad. Dermatol.57(4), 703706 (2007).
45. Kuldeep C, Singhal H, Khare AK, Mittal A, Gupta LK, Garg A. Randomized comparison of topical
betamethasone valerate foam, intralesional triamcinolone acetonide and tacrolimus ointment in
management of localized alopecia areata. Int. J. Trichology 3(1), 2024 (2011).
46. Ait Ourhroui M, Hassam B, Khoudri I. Treatment of alopecia areata with prednisone in a oncemonthly oral pulse. Ann. Dermatol. Venereol. 137(89), 514518 (2010).
47. Kang H, Wu W, Lo B et al. Hair follicles from alopecia areata patients exhibit alterations in
immune privilege associated gene expression in advance of hair loss. J. Invest.
Dermatol. 130(11), 25352537 (2010).
48. Das S, Ghorami RC, Chatterjee T, Banerjee G. Comparative assessment of topical steroids,
topical tretenoin (0.05%) and dithranol paste in alopecia areata. Indian J. Dermatol. 55(2), 148
149 (2010).
49. Efentaki P, Altenburg A, Haerting J, Zouboulis CC. Medium-dose prednisolone pulse therapy in
alopecia areata.Dermatoendocrinol. 1(6), 310313 (2009).
50. Tosti A, Duque-Estrada B. Treatment strategies for alopecia. Expert Opin. Pharmacother. 10(6),
10171026 (2009).
51. Chang KH, Rojhirunsakool S, Goldberg LJ. Treatment of severe alopecia areata with
intralesional steroid injections. J. Drugs Dermatol. 8(10), 909912 (2009).
52. Barak Y, Amiran MD, Fineberg E, Lang Y. Perforating eye injury caused by a Dermojet
syringe. Arch. Dermatol.145(8), 958960 (2009).
53. Flessner CA, Lochner C, Stein DJ, Woods DW, Franklin ME, Keuthen NJ. Age of onset of
trichotillomania symptoms: investigating clinical correlates. J. Nerv. Ment. Dis. 198(12), 896900
(2010).
54. Murphy C, Redenius R, O'Neill E, Zallek S. Sleep-isolated trichotillomania: a survey of
dermatologists. J. Clin. Sleep Med. 3(7), 719721 (2007).
55. Bloch MH, Landeros-Weisenberger A, Dombrowski P, Kelmendi B, Wegner R, Nudel J.
Systematic review: pharmacological and behavioral treatment for trichotillomania. Biol.
Psychiatry 62(8), 839846 (2007).
56. Rahman O, Toufexis M, Murphy TK, Storch EA. Behavioral treatment of trichotillomania and
trichophagia in a 29-month-old girl. Clin. Pediatr. (Phila.) 48, 951953 (2009).
57. Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of
trichotillomania: a double-blind, placebo-controlled study. Arch. Gen. Psychiatry 66(7), 756763
(2009).
58. Grant JE, Odlaug BL, Chamberlain SR, Kim SW. Dronabinol, a cannabinoid agonist, reduces
hair pulling in trichotillomania: a pilot study. Psychopharmacology (Berl.) doi:10.1007/s00213011-2347-8 (2011) (Epub ahead of print).
59. Grant JE, Odlaug BL. Update on pathological skin picking. Curr. Psychiatry Rep. 11(4), 283288
(2009).
60. Van Ameringen M, Mancini C, Patterson B, Bennett M, Oakman J. A randomized, double-blind,
placebo-controlled trial of olanzapine in the treatment of trichotillomania. J. Clin.
Psychiatry 71(10), 13361343 (2010).
61. Leombruni P, Gastaldi F. Oxcarbazepine for the treatment of trichotillomania. Clin.
Neuropharmacol. 33(2), 107108 (2010).
62. Franklin ME, Zagrabbe K, Benavides KL. Trichotillomania and its treatment: a review and
recommendations.Expert Rev. Neurother. 11(8), 11651174 (2011).
63. Khumalo NP, Ngwanya RM. Traction alopecia: 2% topical minoxidil shows promise. Report of
two cases. J. Eur. Acad. Dermatol. Venereol. 21(3), 433434 (2007).
64. Khumalo NP, Jessop S, Gumedze F, Ehrlich R. Determinants of marginal traction alopecia in
African girls and women. J. Am. Acad. Dermatol. 59(3), 432438 (2008).
65. Nam-Cha SH, Guhl G, Fernndez-Pea P, Fraga J. Alopecia syphilitica with detection
of Treponema pallidum in the hair follicle. J. Cutan. Pathol. 34(Suppl. 1), 3740 (2007).
66. Ochoa BE, King LE Jr, Price VH. Lichen planopilaris: annual incidence in four hair referral
centers in the United States. J. Am. Acad. Dermatol. 58(2), 352353 (2008).
67. Estrada BD, Tamler C, Sodre CT, Barcaui CB, Pereira FB. Dermoscopy patterns of cicatricial
alopecia resulting from discoid lupus erythematosus and lichen planopilaris. An. Bras.
Dermatol. 85(2), 179183 (2010).
68. Chiang C, Sah D, Cho BK, Ochoa BE, Price VH. Hydroxychloroquine and lichen planopilaris:
efficacy and introduction of Lichen Planopilaris Activity Index scoring system. J. Am. Acad.
Dermatol. 62(3), 387392 (2010).
69. Crisstomo MR, Crisstomo MC, Crisstomo MG, Gondim VJ, Benevides AN. Hair loss due to
lichen planopilaris after hair transplantation: a report of two cases and a literature review. An.
Bras. Dermatol. 86(2), 359362 (2011).
70. Tollefson MM, Witman PM. En coup de sabre morphea and Parry-Romberg syndrome: a
retrospective review of 54 patients. J. Am. Acad. Dermatol. 56(2), 257263 (2007).
71. Yamazaki M, Irisawa R, Tsuboi R. Temporal triangular alopecia and a review of 52 past cases. J.
Dermatol.37(4), 360362 (2010).
72. Bilginer B, Onal MB, Bahadir S, Akalan N. Aplasia cutis congenita of the scalp, skull and dura
associated with AdamsOliver syndrome. Turk. Neurosurg. 18(2), 191193 (2008).
73. Neri I, Savoia F, Giacomini F, Raone B, Aprile S, Patrizi A. Usefulness of dermatoscopy for the
early diagnosis of sebaceous naevus and differentiation from aplasia cutis congenita. Clin. Exp.
Dermatol. 34(5), 5052 (2009).
74. Hamm H, Hger PH. Skin tumors in childhood. Dtsch. Arztebl. Int. 108(20), 347353 (2011).
75. Berbert AL, Mantese SA, Rocha A, Cherin CP, Couto CM. Keratosis follicularis spinulosa
decalvans: case report. An. Bras. Dermatol. 85(4), 537540 (2010).
76. Thomas M, Daniel S. Atrichia congenita with papular lesions. Indian J. Dermatol. Venereol.
Leprol. 77(1), 7072 (2011).
77. Chabchoub I, Ayadi L, Mejdoub I et al. Alopecia, congenital ichthyosis, and growth delay, what is
the diagnosis?Arch. Pediatr. 17(12), 16851686 (2010).
78. Redler S, Kruse R, Eigelshoven et al. Marie Unna hereditary hypotrichosis: identification of
a U2HR mutation in the family from the original 1925 report. J. Am. Acad. Dermatol. 64(4), 45
50 (2011).
79. Halverstam CP, Vachharajani A, Mallory SB. Cushing syndrome from percutaneous absorption
of 1% hydrocortisone ointment in Netherton syndrome. Pediatr. Dermatol. 24(1), 4245 (2007).
80. Larregue M, Guillet G. [Collodion baby with neonatal signs of trichothiodystrophy misdiagnosed
as Netherton syndrome: reassessment of a previous diagnostic error]. Ann. Dermatol.
Venereol. 134(3), 245248 (2007).
81. Komatsu N, Saijoh K, Jayakumar A et al. Correlation between SPINK5 gene mutations and
clinical manifestations in Netherton syndrome patients. J. Invest. Dermatol. 128(5), 11481159
(2008).
82. Burk C, Hu S, Lee C, Connelly EA. Netherton syndrome and trichorrhexis invaginata a novel
diagnostic approach. Pediatr. Dermatol. 25(2), 287288 (2008).
83. Cosimo QC, Daniela L, Elsa B, Carlo DV, Giuseppe F. Kinky hair, kinky vessels, and bladder
diverticula in Menkes disease. J. Neuroimaging 21(2), 114116 (2011).
84. Price DJ, Ravindranath T, Kaler SG. Internal jugular phlebectasia in Menkes disease. Int. J.
Pediatr. Otorhinolaryngol. 71(7), 11451148 (2007).
85. Balestracci A, Caletti MG, Missoni M. A case of Menkes' disease with nephrocalcinosis and
chronic renal failure.Pediatr. Nephrol. 24(6), 12551256 (2009).
86. La Fontaine S, Mercer JF. Trafficking of the copper-ATPases, ATP7A and ATP7B: role in copper
homeostasis.Arch. Biochem. Biophys. 463(2), 149167 (2007).
87. Bertini I, Rosato A. Menkes disease. Cell Mol. Life Sci. 65(1), 8991 (2008).
88. Kaler SG, Holmes CS, Goldstein DS et al. Neonatal diagnosis and treatment of Menkes
disease. N. Engl. J. Med. 358(6), 605614 (2008).
105.
Garza LA, Yang CC, Zhao T et al. Bald scalp in men with androgenetic alopecia retains
hair follicle stem cells but lacks CD200-rich and CD34-positive hair follicle progenitor cells. J.
Clin. Invest. 121(2), 613622 (2011).